Pre-made Apamistamab benchmark antibody ( Whole mAb Radiolabelled, anti-PTPRC therapeutic antibody, Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Apamistamab biosimilar, Whole mAb Radiolabelled, Anti-PTPRC Antibody: Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

The investigational drug 131-I apamistamab is a protein combined with a radioactive form of iodine, which gives off a small amount of radiation. … It kills them, which prevents them from making other proteins associated with the side effects seen in some people who receive CAR T-cell therapy.